1004 related articles for article (PubMed ID: 16878047)
1. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
2. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
Krentz HB; Kliewer G; Gill MJ
HIV Med; 2005 Mar; 6(2):99-106. PubMed ID: 15807715
[TBL] [Abstract][Full Text] [Related]
3. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
4. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
[TBL] [Abstract][Full Text] [Related]
5. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
Brady MT; Oleske JM; Williams PL; Elgie C; Mofenson LM; Dankner WM; Van Dyke RB;
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):86-94. PubMed ID: 20035164
[TBL] [Abstract][Full Text] [Related]
6. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
[TBL] [Abstract][Full Text] [Related]
7. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.
Sabin CA; Smith CJ; Youle M; Lampe FC; Bell DR; Puradiredja D; Lipman MC; Bhagani S; Phillips AN; Johnson MA
AIDS; 2006 Jan; 20(1):67-71. PubMed ID: 16327321
[TBL] [Abstract][Full Text] [Related]
8. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.
Palella FJ; Baker RK; Buchacz K; Chmiel JS; Tedaldi EM; Novak RM; Durham MD; Brooks JT;
AIDS; 2011 Sep; 25(15):1865-76. PubMed ID: 21811144
[TBL] [Abstract][Full Text] [Related]
9. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
10. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Yephthomi T; Pradeep A; Saghayam S; Flanigan T; Mayer KH; Solomon S
Int J Infect Dis; 2010 Feb; 14(2):e127-31. PubMed ID: 19632872
[TBL] [Abstract][Full Text] [Related]
12. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.
Croxford S; Kitching A; Desai S; Kall M; Edelstein M; Skingsley A; Burns F; Copas A; Brown AE; Sullivan AK; Delpech V
Lancet Public Health; 2017 Jan; 2(1):e35-e46. PubMed ID: 29249478
[TBL] [Abstract][Full Text] [Related]
13. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.
Bonnet F; Morlat P; Chêne G; Mercié P; Neau D; Chossat I; Decoin M; Djossou F; Beylot J; Dabis F;
HIV Med; 2002 Jul; 3(3):195-9. PubMed ID: 12139658
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
15. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.
Crum NF; Riffenburgh RH; Wegner S; Agan BK; Tasker SA; Spooner KM; Armstrong AW; Fraser S; Wallace MR;
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):194-200. PubMed ID: 16394852
[TBL] [Abstract][Full Text] [Related]
17. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
18. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
[TBL] [Abstract][Full Text] [Related]
19. Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.
Pinto AN; Grey P; Shaik A; Cooper DA; Kelleher AD; Petoumenos K
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):936-941. PubMed ID: 29901415
[TBL] [Abstract][Full Text] [Related]
20. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
